Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies demonstrating efficacy in this setting. However, ther...
Enregistré dans:
Auteurs principaux: | Russell Sterrett, Amarilis Figueiredo, Ranjeeta Mallick, Natasha Kekre, Harold Atkins, Arleigh McCurdy |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/855b6e849f604315b0e9b1d6256a2e6b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
par: Schoenbeck KL, et autres
Publié: (2020) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
par: Bhutani D, et autres
Publié: (2017) -
Therapy of Angiosarcoma with Thalidomide and Lenalidomide
par: M. Jules Mattes, et autres
Publié: (2021) -
Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
par: Hua Li, et autres
Publié: (2021) -
Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
par: Peña,Camila, et autres
Publié: (2018)